全文获取类型
收费全文 | 138310篇 |
免费 | 10629篇 |
国内免费 | 236篇 |
专业分类
耳鼻咽喉 | 1426篇 |
儿科学 | 3723篇 |
妇产科学 | 2794篇 |
基础医学 | 21169篇 |
口腔科学 | 3801篇 |
临床医学 | 11884篇 |
内科学 | 28047篇 |
皮肤病学 | 2362篇 |
神经病学 | 13609篇 |
特种医学 | 5617篇 |
外国民族医学 | 9篇 |
外科学 | 17676篇 |
综合类 | 754篇 |
现状与发展 | 1篇 |
一般理论 | 116篇 |
预防医学 | 15543篇 |
眼科学 | 2210篇 |
药学 | 8343篇 |
1篇 | |
中国医学 | 241篇 |
肿瘤学 | 9849篇 |
出版年
2023年 | 582篇 |
2022年 | 459篇 |
2021年 | 2022篇 |
2020年 | 1604篇 |
2019年 | 2274篇 |
2018年 | 2862篇 |
2017年 | 2412篇 |
2016年 | 2614篇 |
2015年 | 2891篇 |
2014年 | 4018篇 |
2013年 | 5406篇 |
2012年 | 8192篇 |
2011年 | 8342篇 |
2010年 | 4373篇 |
2009年 | 4552篇 |
2008年 | 7506篇 |
2007年 | 7743篇 |
2006年 | 7525篇 |
2005年 | 7135篇 |
2004年 | 6210篇 |
2003年 | 5918篇 |
2002年 | 5441篇 |
2001年 | 4566篇 |
2000年 | 4457篇 |
1999年 | 3986篇 |
1998年 | 1638篇 |
1997年 | 1342篇 |
1996年 | 1416篇 |
1995年 | 1274篇 |
1994年 | 1177篇 |
1993年 | 1056篇 |
1992年 | 2775篇 |
1991年 | 2500篇 |
1990年 | 2372篇 |
1989年 | 2196篇 |
1988年 | 2031篇 |
1987年 | 1775篇 |
1986年 | 1702篇 |
1985年 | 1639篇 |
1984年 | 1229篇 |
1983年 | 1087篇 |
1982年 | 670篇 |
1981年 | 584篇 |
1980年 | 539篇 |
1979年 | 926篇 |
1978年 | 625篇 |
1977年 | 511篇 |
1974年 | 480篇 |
1973年 | 462篇 |
1972年 | 421篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Edwin van der Pol Joshua A. Welsh Rienk Nieuwland 《Journal of thrombosis and haemostasis》2022,20(1):245-251
The Extracellular Vesicle Flow Cytometry Working Group ( http://www.evflowcytometry.org ) is formed by members of the International Society for Extracellular Vesicles (ISEV), the International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH). This working group of flow cytometry experts develops guidelines for best practices regarding flow cytometry detection of extracellular vesicles. To improve rigor and standardization, this working group published a framework outlining the minimal information to report about a flow cytometry experiment on extracellular vesicles (MIFlowCyt-EV) in the Journal of Extracellular Vesicles, the ISEV journal, in 2020. In parallel, an article explaining MIFlowCyt-EV was published in Cytometry Part A, one of the ISAC journals, and now will be introduced to the ISTH as an SSC Communication in the Journal of Thrombosis and Haemostasis. The goal of this SSC Communication is to explain why flow cytometry is becoming the instrument of choice to characterize single extracellular vesicles, the obstacles that have been identified and (mostly) overcome by developing procedures to calibrate flow cytometers, and the relevance of reporting minimal information to improve reliability and reproducibility of experiments in which flow cytometers are used for characterization of extracellular vesicles. 相似文献
2.
3.
Keith B. Diamond Ivan J. Golub Asad M. Ashraf Samuel J. Swiggett Paul V. Romeo Jack Choueka 《Seminars in Arthroplasty》2022,32(1):15-22
BackgroundWhile studies have demonstrated favorable outcomes in utilization of primary total shoulder arthroplasty (TSA) for the treatment of glenohumeral osteoarthritis (OA), adverse events such as infections can still occur. Periprosthetic joint infections (PJIs) are associated with worse outcomes and patient morbidity. The purpose of this study was to: (1) compare patient demographics amongst TSA patients with and without PJIs following primary TSA; and (2) identify patient-related risk factors for PJIs following primary TSA.MethodsPatients undergoing primary TSA for the treatment of glenohumeral OA were identified using the Mariner administrative claims database by CPT code 23,472. Laterality modifiers were utilized to ensure PJIs were developing in the correct laterality as those patients undergoing primary TSA. Inclusion for the study group consisted of patients who developed PJIs within 2-years after the index procedure, whereas patients who did not develop PJIs served as the comparison cohort. Primary outcomes analyzed included patient demographics and patient-related risk factors for PJIs following primary TSA. A stepwise backwards elimination multivariate binomial logistic regression analyses was performed to determine the odds (OR) of PJIs in patients undergoing primary TSA. A P value less than .05 was considered statistically significant.ResultsThe query yielded 15,396 patients who underwent primary TSA for glenohumeral OA, of which 191 patients developed PJIs and 15,205 did not develop PJIs. The study found statistically significant differences amongst patients who did and did not develop PJIs following primary TSA with respect to age, sex, and presence of comorbid conditions. Risk factors associated with developing PJIs following primary TSA included: pathologic weight loss (OR: 2.06, P < .0001), obesity (OR: 1.56, P = .0001), male sex (OR: 1.52, P = .007), and peripheral vascular disease (OR: 1.46, P = .022).ConclusionAs the number of primary TSAs for the treatment of glenohumeral OA increase worldwide, identifying modifiable risk-factors to reduce the incidence of infection is critical. The study found various modifiable and non-modifiable risk factors associated with developing PJIs following primary TSA. This study is valuable to orthopedists in order to identify and risk-stratify patients with regard to PJI in the setting of primary TSA for OA.Level of EvidenceLevel III; Case-Control Study 相似文献
4.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
5.
6.
7.
Two-year results after combined phacoemulsification and iris-fixated phakic intraocular lens removal
Gaurisankar Zoraida Solaiga van Rijn Gwyneth A. Cheng Yanny Y. Y. Luyten Gregorius P. M. Beenakker Jan-Willem M. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(4):1367-1375
Graefe's Archive for Clinical and Experimental Ophthalmology - To describe and present results after a technique for cataract surgery combined with explantation of an iris-fixated phakic... 相似文献
8.
9.